Pharmaceutical Technology

JUNE 13, 2025

The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir) for treating adults and paediatric patients three years and older with acute or chronic hepatitis C virus (HCV) infection. Credit: © AbbVie Inc. All rights reserved.

Labelling 52

Labelling FDA Communication Hospitals 52

Pharmaceutical Technology

JULY 8, 2025

How will RFK Jr’s American dream for vaccines play out? Chugai president and CEO Dr Osamu Okuda stated: “We believe that open innovation with external partners, including leading global players, is extremely important for achieving global first-class drug discovery outlined in our growth strategy toward 2030, TOP I 2030. “By

Packaging 52

Packaging Immunization Hospitals Communication 52

PharmTech

JULY 4, 2025

While treatments for infection, inflammation, high eye pressure, and neovascularization have been shown to be effective, this method of delivery is considered “off-label,” as FDA has not approved products specifically for this use, except two intracameral implants (see below). In addition, many patients are hesitant to receive eye injections.

Dosage 64

Dosage FDA Vaccines Pharmaceutical Companies 64

ISPE

SEPTEMBER 29, 2023

For more than 240 years, Takeda has focused on delivering transformative treatments in the therapeutic areas of gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Labelling Patient Care 52

PharmTech

JUNE 26, 2025

million) in non-dilutive funding through i-Nov, an innovation competition and flagship French government program that is part of the France 2030 initiative, operated by Bpifrance (1). million (approximately US$1.99 The company said in June 2025 that it raised €11.25 million (US$12.9 Pluta ; Nishant B. Pluta ; Nishant B.

Dosage 59

Dosage Vaccines Compounding Labelling 59

Drug Topics

JUNE 12, 2025

The FDA approved a label expansion for glecaprevir/pibrentasvir (Mavyret) to treat acute hepatitis C virus (HCV) infection in patients 3 years of age and older with compensated cirrhosis or without cirrhosis, AbbVie announced in a release. Passport to Protection: Best Practices for Travel Vaccines in the Pharmacy Setting Gretchen K.

FDA 315

FDA Vaccines Labelling Specialty Pharmacies 315

Pharmaceutical Technology

JULY 4, 2025

How will RFK Jr’s American dream for vaccines play out? Tensions escalated in late January when the company scrapped a £450m plan to turn its Speke-based facility into a major vaccine hub, after failing to reach an agreement with government ministers over the level of state support.

Chemotherapy 52

Chemotherapy Packaging Labelling Communication 52